Xiaofang Pharmaceutical disclosed its 2026 semi-annual report on August 27. In the first half, it achieved total operating revenue of 282 million yuan, up 4.50 percent year on year. Net profit attributable to the parent company was 106 million yuan, down 12.64 percent year on year. Net profit after deducting non-recurring items was 106 million yuan, down 12.87 percent year on year. Net cash flow from operating activities was 97.7353 million yuan, up 8.28 percent year on year. The company plans to distribute a cash dividend of 3.9 yuan per 10 shares, tax included, to all shareholders. As of the end of the first half of 2026, the company's basic earnings per share were 0.66 yuan, and the weighted average return on equity was 9.29 percent.
XIAO FANG ORD A (SHH) EQSW Exp:Net profit fell 12.64% year on year, though revenue grew and dividend announced.
